<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC11294966</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC11294966.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">11294966</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">11294966</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">39088212</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1001/jamanetworkopen.2024.26872</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">zoi240835</article-id></all-ids><extracted-table><table-id>zoi240835t1</table-id><table-label>Table 1. </table-label><table-caption>Baseline Demographic and Clinical Characteristicsa</table-caption><table-wrap-foot>SI conversion factor: To convert polyunsaturated fatty acid to millimoles per liter, multiply by 0.0355.aBaseline covariates were evaluated and confirmed for balance across the 2 groups using t-statistics for continuous variables and χ2 statistics for categorical variables (sex, race/ethnicity, education, apolipoprotein E ε4 status, Clinical Dementia Rating of 0, histories).bBody mass index is calculated as weight in kilograms divided by height in meters squared.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="zoi240835t1" orientation="portrait"><label>Table 1. </label><caption><title>Baseline Demographic and Clinical Characteristics<xref rid="zoi240835t1n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="57.39%" span="1"/><col width="23.48%" span="1"/><col width="19.13%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Participants, No. (%) (N = 102)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">ω-3 (n = 51)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo (n = 51)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD) [range], y</td><td valign="top" align="left" rowspan="1" colspan="1">81.2 (4.4) [75-96]</td><td valign="top" align="left" rowspan="1" colspan="1">81.1 (4.4) [75-93]</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">31 (60.8)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (60.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">20 (39.2)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (39.2)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race and ethnicity</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> African American or Black</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td><td valign="top" align="left" rowspan="1" colspan="1">3 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White, Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">3 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White, Non-Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">44 (86.3)</td><td valign="top" align="left" rowspan="1" colspan="1">50 (98.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Education</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> High school graduate or less</td><td valign="top" align="left" rowspan="1" colspan="1">14 (27.5)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (19.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Some college</td><td valign="top" align="left" rowspan="1" colspan="1">9 (17.6)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (21.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> College graduate or advanced degree</td><td valign="top" align="left" rowspan="1" colspan="1">28 (54.9)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (58.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Systolic blood pressure, mean (SD), mm Hg</td><td valign="top" align="left" rowspan="1" colspan="1">146.7 (13.7)</td><td valign="top" align="left" rowspan="1" colspan="1">145.2 (18.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Diastolic blood pressure, mean (SD), mm Hg</td><td valign="top" align="left" rowspan="1" colspan="1">68.9 (10.7)</td><td valign="top" align="left" rowspan="1" colspan="1">70.7 (13.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Body mass index, mean (SD)<xref rid="zoi240835t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">27.4 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">26.2 (3.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Apolipoprotien E ε4 carrier</td><td valign="top" align="left" rowspan="1" colspan="1">13 (25.5)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (29.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Plasma ω-3 polyunsaturated fatty acid (20:5 + 22:6), mean (SD), mg/dL</td><td valign="top" align="left" rowspan="1" colspan="1">7.135 (2.448)</td><td valign="top" align="left" rowspan="1" colspan="1">6.662 (2.176)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mini-Mental State Exam score, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">27.6 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">28.2 (1.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Montreal Cognitive Assessment score, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">24.0 (3.2)</td><td valign="top" align="left" rowspan="1" colspan="1">24.7 (3.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Clinical Dementia Rating of 0</td><td valign="top" align="left" rowspan="1" colspan="1">35 (68.6)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (70.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Instrumental Activities of Daily Living, mean (SD), No.</td><td valign="top" align="left" rowspan="1" colspan="1">0.1 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.1 (0.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Geriatric Depression Scale score, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">1.6 (1.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.3 (1.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of depression</td><td valign="top" align="left" rowspan="1" colspan="1">11 (21.6)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (23.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of hypertension</td><td valign="top" align="left" rowspan="1" colspan="1">39 (76.4)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (68.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of vascular disease</td><td valign="top" align="left" rowspan="1" colspan="1">8 (15.7)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (13.7)</td></tr></tbody></table><table-wrap-foot><p>SI conversion factor: To convert polyunsaturated fatty acid to millimoles per liter, multiply by 0.0355.</p><fn id="zoi240835t1n1"><label><sup>a</sup></label><p>Baseline covariates were evaluated and confirmed for balance across the 2 groups using t-statistics for continuous variables and χ<sup>2</sup> statistics for categorical variables (sex, race/ethnicity, education, apolipoprotein E ε4 status, Clinical Dementia Rating of 0, histories).</p></fn><fn id="zoi240835t1n2"><label><sup>b</sup></label><p>Body mass index is calculated as weight in kilograms divided by height in meters squared.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1. <div xmlns="http://www.w3.org/1999/xhtml" class="caption">Baseline Demographic and Clinical Characteristics???</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col width="57.39%"/><col width="23.48%"/><col width="19.13%"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col">Characteristic</th><th colspan="2" valign="top" align="left" scope="colgroup">Participants, No. (%) (N = 102)</th></tr><tr><th valign="top" align="left" scope="colgroup">ω-3 (n = 51)</th><th valign="top" align="left" scope="col">Placebo (n = 51)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row">Age, mean (SD) [range], y</td><td valign="top" align="left">81.2 (4.4) [75-96]</td><td valign="top" align="left">81.1 (4.4) [75-93]</td></tr><tr><td valign="top" align="left" scope="col">Sex</td><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left" scope="row"> Female</td><td valign="top" align="left">31 (60.8)</td><td valign="top" align="left">31 (60.8)</td></tr><tr><td valign="top" align="left" scope="row"> Male</td><td valign="top" align="left">20 (39.2)</td><td valign="top" align="left">20 (39.2)</td></tr><tr><td valign="top" align="left" scope="col">Race and ethnicity</td><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left" scope="row"> African American or Black</td><td valign="top" align="left">1 (2.0)</td><td valign="top" align="left">0</td></tr><tr><td valign="top" align="left" scope="row"> Asian</td><td valign="top" align="left">3 (5.9)</td><td valign="top" align="left">0</td></tr><tr><td valign="top" align="left" scope="row"> White, Hispanic</td><td valign="top" align="left">3 (5.9)</td><td valign="top" align="left">1 (2.0)</td></tr><tr><td valign="top" align="left" scope="row"> White, Non-Hispanic</td><td valign="top" align="left">44 (86.3)</td><td valign="top" align="left">50 (98.0)</td></tr><tr><td valign="top" align="left" scope="col">Education</td><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left" scope="row"> High school graduate or less</td><td valign="top" align="left">14 (27.5)</td><td valign="top" align="left">10 (19.6)</td></tr><tr><td valign="top" align="left" scope="row"> Some college</td><td valign="top" align="left">9 (17.6)</td><td valign="top" align="left">11 (21.6)</td></tr><tr><td valign="top" align="left" scope="row"> College graduate or advanced degree</td><td valign="top" align="left">28 (54.9)</td><td valign="top" align="left">30 (58.8)</td></tr><tr><td valign="top" align="left" scope="row">Systolic blood pressure, mean (SD), mm Hg</td><td valign="top" align="left">146.7 (13.7)</td><td valign="top" align="left">145.2 (18.6)</td></tr><tr><td valign="top" align="left" scope="row">Diastolic blood pressure, mean (SD), mm Hg</td><td valign="top" align="left">68.9 (10.7)</td><td valign="top" align="left">70.7 (13.0)</td></tr><tr><td valign="top" align="left" scope="row">Body mass index, mean (SD)???</td><td valign="top" align="left">27.4 (4.8)</td><td valign="top" align="left">26.2 (3.8)</td></tr><tr><td valign="top" align="left" scope="row">Apolipoprotien E ε4 carrier</td><td valign="top" align="left">13 (25.5)</td><td valign="top" align="left">15 (29.4)</td></tr><tr><td valign="top" align="left" scope="row">Plasma ω-3 polyunsaturated fatty acid (20:5 + 22:6), mean (SD), mg/dL</td><td valign="top" align="left">7.135 (2.448)</td><td valign="top" align="left">6.662 (2.176)</td></tr><tr><td valign="top" align="left" scope="row">Mini-Mental State Exam score, mean (SD)</td><td valign="top" align="left">27.6 (1.7)</td><td valign="top" align="left">28.2 (1.8)</td></tr><tr><td valign="top" align="left" scope="row">Montreal Cognitive Assessment score, mean (SD)</td><td valign="top" align="left">24.0 (3.2)</td><td valign="top" align="left">24.7 (3.0)</td></tr><tr><td valign="top" align="left" scope="row">Clinical Dementia Rating of 0</td><td valign="top" align="left">35 (68.6)</td><td valign="top" align="left">36 (70.6)</td></tr><tr><td valign="top" align="left" scope="row">Instrumental Activities of Daily Living, mean (SD), No.</td><td valign="top" align="left">0.1 (0.5)</td><td valign="top" align="left">0.1 (0.2)</td></tr><tr><td valign="top" align="left" scope="row">Geriatric Depression Scale score, mean (SD)</td><td valign="top" align="left">1.6 (1.6)</td><td valign="top" align="left">1.3 (1.3)</td></tr><tr><td valign="top" align="left" scope="row">History of depression</td><td valign="top" align="left">11 (21.6)</td><td valign="top" align="left">12 (23.5)</td></tr><tr><td valign="top" align="left" scope="row">History of hypertension</td><td valign="top" align="left">39 (76.4)</td><td valign="top" align="left">35 (68.6)</td></tr><tr><td valign="top" align="left" scope="row">History of vascular disease</td><td valign="top" align="left">8 (15.7)</td><td valign="top" align="left">7 (13.7)</td></tr></tbody></table></div>SI conversion factor: To convert polyunsaturated fatty acid to millimoles per liter, multiply by 0.0355.aBaseline covariates were evaluated and confirmed for balance across the 2 groups using t-statistics for continuous variables and χ2 statistics for categorical variables (sex, race/ethnicity, education, apolipoprotein E ε4 status, Clinical Dementia Rating of 0, histories).bBody mass index is calculated as weight in kilograms divided by height in meters squared.</transformed-table></extracted-table><extracted-table><table-id>zoi240835t2</table-id><table-label>Table 2. </table-label><table-caption>ω-3 Polyunsaturated Fatty Acid Effects on the Main Outcomes in All Participants and by APOE*E4 Carrier Status Over 3 Years Under the Intention to Treat Protocola</table-caption><table-wrap-foot>Abbreviation: APOE*E4, apolipoprotein E ε4 allele.aThe intention-to-treat cohort includes all randomly assigned participants with at least 1 follow-up magnetic resonance imaging scan (n = 87).bAnnualized changes were calculated from primary mixed-effects models as time trajectories for ω-3 and placebo groups.cLinear response difference was taken as the treatment-time interaction coefficient from the primary mixed-effects models.dOmega-3 treatment effect sizes were taken as the t-statistic from the primary mixed-effects model for the treatment-time interaction.eCohen d was calculated from the primary mixed-effects models using t-statistic and appropriate df for each outcome.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="zoi240835t2" orientation="portrait"><label>Table 2. </label><caption><title>ω-3 Polyunsaturated Fatty Acid Effects on the Main Outcomes in All Participants and by <italic toggle="yes">APOE*E4</italic> Carrier Status Over 3 Years Under the Intention to Treat Protocol<xref rid="zoi240835t2n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="18.27%" span="1"/><col width="21.74%" span="1"/><col width="23.48%" span="1"/><col width="22.61%" span="1"/><col width="8.69%" span="1"/><col width="5.21%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Annual change (95% CI)<xref rid="zoi240835t2n2" ref-type="table-fn"><sup>b</sup></xref></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Linear difference between groups, coefficient estimate (95% CI)<xref rid="zoi240835t2n3" ref-type="table-fn"><sup>c</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">ω-3 Effect size estimates</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">ω-3 Group</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo group</th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1"><italic toggle="yes">t</italic> Statistic (<italic toggle="yes">P</italic> value)<xref rid="zoi240835t2n4" ref-type="table-fn"><sup>d</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Cohen <italic toggle="yes">d</italic><xref rid="zoi240835t2n5" ref-type="table-fn"><sup>e</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Primary outcome</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White matter lesion, total, cm<sup>3</sup> (log)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0782 (0.0414 to 0.1151)</td><td valign="top" align="left" rowspan="1" colspan="1">1.0000 (0.0638 to 0.1357)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0216 (−0.0624 to 0.0191)</td><td valign="top" align="left" rowspan="1" colspan="1">−1.04 (.30)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.24</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> positive</td><td valign="top" align="left" rowspan="1" colspan="1">0.0417 (−0.0362 to 0.1197)</td><td valign="top" align="left" rowspan="1" colspan="1">0.1067 (0.0418 to 0.1702)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0650 (−0.1522 to 0.0195)</td><td valign="top" align="left" rowspan="1" colspan="1">−1.50 (.15)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.63</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> negative</td><td valign="top" align="left" rowspan="1" colspan="1">0.0917 (0.0497 to 0.1337)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0980 (0.0543 to 0.1410)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0064 (−0.0515 to 0.0394)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.27 (.79)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.07</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Secondary outcomes</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diffusion tenor imaging of fractional anisotropy, mm<sup>2</sup>/s</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0014 (−0.0027 to 0.0002)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0027 (−0.0041 to −0.0014)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0014 (−0.0001 to 0.0028)</td><td valign="top" align="left" rowspan="1" colspan="1">1.84 (.07)</td><td valign="top" align="left" rowspan="1" colspan="1">0.42</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> positive</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0015 (−0.0041 to 0.0011)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0047 (−0.0067 to −0.0025)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0032 (0.0004 to 0.0062)</td><td valign="top" align="left" rowspan="1" colspan="1">2.22 (.04)</td><td valign="top" align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> negative</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0012 (−0.0028 to 0.0004)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0016 (−0.0032 to 0.0020)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0004 (−0.0013 to 0.0020)</td><td valign="top" align="left" rowspan="1" colspan="1">0.44 (.66)</td><td valign="top" align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medial temporal, cm<sup>3</sup></td><td valign="top" align="left" rowspan="1" colspan="1">−0.3664 (−0.4832 to −0.2496)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.3585 (−0.4731 to −0.2434)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0079 (−0.1289 to 0.1134)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.13 (.90)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.03</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> positive</td><td valign="top" align="left" rowspan="1" colspan="1">−0.5656 (−0.7850 to −0.3462)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.4120 (−0.5922 to −0.2295)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.1536 (−0.3807 to 0.07412)</td><td valign="top" align="left" rowspan="1" colspan="1">−1.31 (.20)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.56</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> negative</td><td valign="top" align="left" rowspan="1" colspan="1">−0.3129 (−0.4540 to −0.1718)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.3306 (−0.4758 to −0.1862)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0178 (−0.1236 to 0.1605)</td><td valign="top" align="left" rowspan="1" colspan="1">0.24 (.81)</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Whole brain, cm<sup>3</sup></td><td valign="top" align="left" rowspan="1" colspan="1">0.5352 (−3.6250 to 4.6960)</td><td valign="top" align="left" rowspan="1" colspan="1">−1.8930 (−6.0280 to 2.1300)</td><td valign="top" align="left" rowspan="1" colspan="1">2.4280 (−2.2360 to 7.2250)</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (.32)</td><td valign="top" align="left" rowspan="1" colspan="1">0.23</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> positive</td><td valign="top" align="left" rowspan="1" colspan="1">−3.0560 (−12.2300 to 6.1200)</td><td valign="top" align="left" rowspan="1" colspan="1">−2.9360 (−10.7800 to 4.7530)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.1193 (−9.2680 to 9.2560)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.03 (.98)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.01</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> negative</td><td valign="top" align="left" rowspan="1" colspan="1">1.2940 (−3.2710 to 5.8580)</td><td valign="top" align="left" rowspan="1" colspan="1">−1.3850 (−6.1210 to 3.1710)</td><td valign="top" align="left" rowspan="1" colspan="1">2.6790 (−2.7500 to 8.2280)</td><td valign="top" align="left" rowspan="1" colspan="1">0.96 (0.34)</td><td valign="top" align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Ventricular, cm<sup>3</sup> (log)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0323 (0.0245 to 0.0401)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0343 (0.0267 to 0.0418)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.0019 (−0.0113 to 0.0076)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.40 (.69)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.09</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> positive</td><td valign="top" align="left" rowspan="1" colspan="1">0.0348 (0.0194 to 0.0502)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0334 (0.0206 to 0.0460)</td><td valign="top" align="left" rowspan="1" colspan="1">0.00138 (−0.0152 to 0.0182)</td><td valign="top" align="left" rowspan="1" colspan="1">0.16 (.87)</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOE*E4</italic> negative</td><td valign="top" align="left" rowspan="1" colspan="1">0.0325 (0.0230 to 0.0421)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0349 (0.0252 to 0.0446)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.00242 (−0.0144 to 0.0097)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.39 (.70)</td><td valign="top" align="left" rowspan="1" colspan="1">−0.11</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: <italic toggle="yes">APOE*E4</italic>, apolipoprotein E ε4 allele.</p><fn id="zoi240835t2n1"><label><sup>a</sup></label><p>The intention-to-treat cohort includes all randomly assigned participants with at least 1 follow-up magnetic resonance imaging scan (n = 87).</p></fn><fn id="zoi240835t2n2"><label><sup>b</sup></label><p>Annualized changes were calculated from primary mixed-effects models as time trajectories for ω-3 and placebo groups.</p></fn><fn id="zoi240835t2n3"><label><sup>c</sup></label><p>Linear response difference was taken as the treatment-time interaction coefficient from the primary mixed-effects models.</p></fn><fn id="zoi240835t2n4"><label><sup>d</sup></label><p>Omega-3 treatment effect sizes were taken as the <italic toggle="yes">t</italic>-statistic from the primary mixed-effects model for the treatment-time interaction.</p></fn><fn id="zoi240835t2n5"><label><sup>e</sup></label><p>Cohen <italic toggle="yes">d</italic> was calculated from the primary mixed-effects models using <italic toggle="yes">t</italic>-statistic and appropriate <italic toggle="yes">df</italic> for each outcome.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2. <div xmlns="http://www.w3.org/1999/xhtml" class="caption">ω-3 Polyunsaturated Fatty Acid Effects on the Main Outcomes in All Participants and by APOE*E4 Carrier Status Over 3 Years Under the Intention to Treat Protocol???</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col width="18.27%"/><col width="21.74%"/><col width="23.48%"/><col width="22.61%"/><col width="8.69%"/><col width="5.21%"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col">Outcome</th><th colspan="2" valign="top" align="left" scope="colgroup">Annual change (95% CI)???</th><th rowspan="2" valign="top" align="left" scope="col">Linear difference between groups, coefficient estimate (95% CI)???</th><th colspan="2" valign="top" align="left" scope="colgroup">ω-3 Effect size estimates</th></tr><tr><th valign="top" align="left" scope="colgroup">ω-3 Group</th><th valign="top" align="left" scope="col">Placebo group</th><th valign="top" align="left" scope="colgroup">t Statistic (P value)???</th><th valign="top" align="left" scope="col">Cohen d???</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col">Primary outcome</td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left" scope="row"> White matter lesion, total, cm3 (log)</td><td valign="top" align="left">0.0782 (0.0414 to 0.1151)</td><td valign="top" align="left">1.0000 (0.0638 to 0.1357)</td><td valign="top" align="left">−0.0216 (−0.0624 to 0.0191)</td><td valign="top" align="left">−1.04 (.30)</td><td valign="top" align="left">−0.24</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 positive</td><td valign="top" align="left">0.0417 (−0.0362 to 0.1197)</td><td valign="top" align="left">0.1067 (0.0418 to 0.1702)</td><td valign="top" align="left">−0.0650 (−0.1522 to 0.0195)</td><td valign="top" align="left">−1.50 (.15)</td><td valign="top" align="left">−0.63</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 negative</td><td valign="top" align="left">0.0917 (0.0497 to 0.1337)</td><td valign="top" align="left">0.0980 (0.0543 to 0.1410)</td><td valign="top" align="left">−0.0064 (−0.0515 to 0.0394)</td><td valign="top" align="left">−0.27 (.79)</td><td valign="top" align="left">−0.07</td></tr><tr><td valign="top" align="left" scope="col">Secondary outcomes</td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left" scope="row"> Diffusion tenor imaging of fractional anisotropy, mm2/s</td><td valign="top" align="left">−0.0014 (−0.0027 to 0.0002)</td><td valign="top" align="left">−0.0027 (−0.0041 to −0.0014)</td><td valign="top" align="left">0.0014 (−0.0001 to 0.0028)</td><td valign="top" align="left">1.84 (.07)</td><td valign="top" align="left">0.42</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 positive</td><td valign="top" align="left">−0.0015 (−0.0041 to 0.0011)</td><td valign="top" align="left">−0.0047 (−0.0067 to −0.0025)</td><td valign="top" align="left">0.0032 (0.0004 to 0.0062)</td><td valign="top" align="left">2.22 (.04)</td><td valign="top" align="left">0.92</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 negative</td><td valign="top" align="left">−0.0012 (−0.0028 to 0.0004)</td><td valign="top" align="left">−0.0016 (−0.0032 to 0.0020)</td><td valign="top" align="left">0.0004 (−0.0013 to 0.0020)</td><td valign="top" align="left">0.44 (.66)</td><td valign="top" align="left">0.08</td></tr><tr><td valign="top" align="left" scope="row"> Medial temporal, cm3</td><td valign="top" align="left">−0.3664 (−0.4832 to −0.2496)</td><td valign="top" align="left">−0.3585 (−0.4731 to −0.2434)</td><td valign="top" align="left">−0.0079 (−0.1289 to 0.1134)</td><td valign="top" align="left">−0.13 (.90)</td><td valign="top" align="left">−0.03</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 positive</td><td valign="top" align="left">−0.5656 (−0.7850 to −0.3462)</td><td valign="top" align="left">−0.4120 (−0.5922 to −0.2295)</td><td valign="top" align="left">−0.1536 (−0.3807 to 0.07412)</td><td valign="top" align="left">−1.31 (.20)</td><td valign="top" align="left">−0.56</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 negative</td><td valign="top" align="left">−0.3129 (−0.4540 to −0.1718)</td><td valign="top" align="left">−0.3306 (−0.4758 to −0.1862)</td><td valign="top" align="left">0.0178 (−0.1236 to 0.1605)</td><td valign="top" align="left">0.24 (.81)</td><td valign="top" align="left">0.04</td></tr><tr><td valign="top" align="left" scope="row"> Whole brain, cm3</td><td valign="top" align="left">0.5352 (−3.6250 to 4.6960)</td><td valign="top" align="left">−1.8930 (−6.0280 to 2.1300)</td><td valign="top" align="left">2.4280 (−2.2360 to 7.2250)</td><td valign="top" align="left">1.01 (.32)</td><td valign="top" align="left">0.23</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 positive</td><td valign="top" align="left">−3.0560 (−12.2300 to 6.1200)</td><td valign="top" align="left">−2.9360 (−10.7800 to 4.7530)</td><td valign="top" align="left">−0.1193 (−9.2680 to 9.2560)</td><td valign="top" align="left">−0.03 (.98)</td><td valign="top" align="left">−0.01</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 negative</td><td valign="top" align="left">1.2940 (−3.2710 to 5.8580)</td><td valign="top" align="left">−1.3850 (−6.1210 to 3.1710)</td><td valign="top" align="left">2.6790 (−2.7500 to 8.2280)</td><td valign="top" align="left">0.96 (0.34)</td><td valign="top" align="left">0.26</td></tr><tr><td valign="top" align="left" scope="row"> Ventricular, cm3 (log)</td><td valign="top" align="left">0.0323 (0.0245 to 0.0401)</td><td valign="top" align="left">0.0343 (0.0267 to 0.0418)</td><td valign="top" align="left">−0.0019 (−0.0113 to 0.0076)</td><td valign="top" align="left">−0.40 (.69)</td><td valign="top" align="left">−0.09</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 positive</td><td valign="top" align="left">0.0348 (0.0194 to 0.0502)</td><td valign="top" align="left">0.0334 (0.0206 to 0.0460)</td><td valign="top" align="left">0.00138 (−0.0152 to 0.0182)</td><td valign="top" align="left">0.16 (.87)</td><td valign="top" align="left">0.07</td></tr><tr><td valign="top" align="left" scope="row">APOE*E4 negative</td><td valign="top" align="left">0.0325 (0.0230 to 0.0421)</td><td valign="top" align="left">0.0349 (0.0252 to 0.0446)</td><td valign="top" align="left">−0.00242 (−0.0144 to 0.0097)</td><td valign="top" align="left">−0.39 (.70)</td><td valign="top" align="left">−0.11</td></tr></tbody></table></div>Abbreviation: APOE*E4, apolipoprotein E ε4 allele.aThe intention-to-treat cohort includes all randomly assigned participants with at least 1 follow-up magnetic resonance imaging scan (n = 87).bAnnualized changes were calculated from primary mixed-effects models as time trajectories for ω-3 and placebo groups.cLinear response difference was taken as the treatment-time interaction coefficient from the primary mixed-effects models.dOmega-3 treatment effect sizes were taken as the t-statistic from the primary mixed-effects model for the treatment-time interaction.eCohen d was calculated from the primary mixed-effects models using t-statistic and appropriate df for each outcome.</transformed-table></extracted-table><extracted-table><table-id>zoi240835t3</table-id><table-label>Table 3. </table-label><table-caption>Adverse Events by Experimental Group</table-caption><table-wrap-foot>aAdverse events are defined according to the Medical Dictionary for Regulatory Activities terminology. Rates between groups across categories were similar (Fisher exact test, P = .60).bFisher exact test, P = .82.cFisher exact test, P = .36.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="zoi240835t3" orientation="portrait"><label>Table 3. </label><caption><title>Adverse Events by Experimental Group</title></caption><table frame="hsides" rules="groups"><col width="70.17%" span="1"/><col width="15.79%" span="1"/><col width="14.04%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Event<xref rid="zoi240835t3n1" ref-type="table-fn"><sup>a</sup></xref></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Participants, No. (%)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">ω-3 (n = 51)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo (n = 51)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">At least 1 serious adverse event</td><td valign="top" align="left" rowspan="1" colspan="1">16 (31.4)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (31.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">At least 1 adverse event</td><td valign="top" align="left" rowspan="1" colspan="1">44 (86.3)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (80.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Serious adverse events</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hospitalizations<xref rid="zoi240835t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">12 (23.5)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (27.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Vascular disorders nonhematological</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">3 (5.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Renal and urinary disorders</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cardiac disorders</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gastrointestinal disorders</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Injury, poisoning, and procedural complications</td><td valign="top" align="left" rowspan="1" colspan="1">4 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Deaths<xref rid="zoi240835t3n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">4 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Injury, poisoning, and procedural complications</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Vascular disorders, nonhematological</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Renal and urinary disorders</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Vascular disorders, hematological</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Neoplasms benign, malignant, and unspecified</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Adverse events</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Injury, poisoning, and procedural complications</td><td valign="top" align="left" rowspan="1" colspan="1">17 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (27.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Musculoskeletal and connective tissue disorders</td><td valign="top" align="left" rowspan="1" colspan="1">12 (23.5)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (27.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gastrointestinal disorders</td><td valign="top" align="left" rowspan="1" colspan="1">10 (19.6)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (29.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nervous system disorders</td><td valign="top" align="left" rowspan="1" colspan="1">12 (23.5)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (25.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Respiratory, thoracic, and mediastinal disorders</td><td valign="top" align="left" rowspan="1" colspan="1">11 (21.5)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (19.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Psychiatric disorders</td><td valign="top" align="left" rowspan="1" colspan="1">9 (17.6)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (15.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Vascular disorders, hematological</td><td valign="top" align="left" rowspan="1" colspan="1">9 (17.6)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (7.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Neoplasms benign, malignant, and unspecified</td><td valign="top" align="left" rowspan="1" colspan="1">5 (9.8)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (15.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> General disorders and administration site conditions</td><td valign="top" align="left" rowspan="1" colspan="1">6 (11.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (7.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cardiac disorders</td><td valign="top" align="left" rowspan="1" colspan="1">3 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (9.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Renal and urinary disorders</td><td valign="top" align="left" rowspan="1" colspan="1">4 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (7.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Infections and infestations</td><td valign="top" align="left" rowspan="1" colspan="1">5 (9.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Surgical and medical procedures</td><td valign="top" align="left" rowspan="1" colspan="1">3 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (7.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Vascular disorders nonhematological</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (9.8)</td></tr></tbody></table><table-wrap-foot><fn id="zoi240835t3n1"><label><sup>a</sup></label><p>Adverse events are defined according to the Medical Dictionary for Regulatory Activities terminology. Rates between groups across categories were similar (Fisher exact test, <italic toggle="yes">P</italic> = .60).</p></fn><fn id="zoi240835t3n2"><label><sup>b</sup></label><p>Fisher exact test, <italic toggle="yes">P</italic> = .82.</p></fn><fn id="zoi240835t3n3"><label><sup>c</sup></label><p>Fisher exact test, <italic toggle="yes">P</italic> = .36.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3. <div xmlns="http://www.w3.org/1999/xhtml" class="caption">Adverse Events by Experimental Group</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col width="70.17%"/><col width="15.79%"/><col width="14.04%"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col">Event???</th><th colspan="2" valign="top" align="left" scope="colgroup">Participants, No. (%)</th></tr><tr><th valign="top" align="left" scope="colgroup">ω-3 (n = 51)</th><th valign="top" align="left" scope="col">Placebo (n = 51)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row">At least 1 serious adverse event</td><td valign="top" align="left">16 (31.4)</td><td valign="top" align="left">16 (31.4)</td></tr><tr><td valign="top" align="left" scope="row">At least 1 adverse event</td><td valign="top" align="left">44 (86.3)</td><td valign="top" align="left">41 (80.4)</td></tr><tr><td valign="top" align="left" scope="col">Serious adverse events</td><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left" scope="row"> Hospitalizations???</td><td valign="top" align="left">12 (23.5)</td><td valign="top" align="left">14 (27.4)</td></tr><tr><td valign="top" align="left" scope="row"> Vascular disorders nonhematological</td><td valign="top" align="left">0</td><td valign="top" align="left">3 (5.8)</td></tr><tr><td valign="top" align="left" scope="row"> Renal and urinary disorders</td><td valign="top" align="left">2 (3.9)</td><td valign="top" align="left">2 (3.9)</td></tr><tr><td valign="top" align="left" scope="row"> Cardiac disorders</td><td valign="top" align="left">2 (3.9)</td><td valign="top" align="left">2 (3.9)</td></tr><tr><td valign="top" align="left" scope="row"> Gastrointestinal disorders</td><td valign="top" align="left">1 (1.9)</td><td valign="top" align="left">0</td></tr><tr><td valign="top" align="left" scope="row"> Injury, poisoning, and procedural complications</td><td valign="top" align="left">4 (7.8)</td><td valign="top" align="left">0</td></tr><tr><td valign="top" align="left" scope="row"> Deaths???</td><td valign="top" align="left">4 (7.8)</td><td valign="top" align="left">1 (1.9)</td></tr><tr><td valign="top" align="left" scope="row"> Injury, poisoning, and procedural complications</td><td valign="top" align="left">1 (1.9)</td><td valign="top" align="left">0</td></tr><tr><td valign="top" align="left" scope="row"> Vascular disorders, nonhematological</td><td valign="top" align="left">0</td><td valign="top" align="left">1 (1.9)</td></tr><tr><td valign="top" align="left" scope="row"> Renal and urinary disorders</td><td valign="top" align="left">1 (1.9)</td><td valign="top" align="left">0</td></tr><tr><td valign="top" align="left" scope="row"> Vascular disorders, hematological</td><td valign="top" align="left">1 (1.9)</td><td valign="top" align="left">0</td></tr><tr><td valign="top" align="left" scope="row"> Neoplasms benign, malignant, and unspecified</td><td valign="top" align="left">1 (1.9)</td><td valign="top" align="left">0</td></tr><tr><td valign="top" align="left" scope="col">Adverse events</td><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left" scope="row"> Injury, poisoning, and procedural complications</td><td valign="top" align="left">17 (33.3)</td><td valign="top" align="left">14 (27.4)</td></tr><tr><td valign="top" align="left" scope="row"> Musculoskeletal and connective tissue disorders</td><td valign="top" align="left">12 (23.5)</td><td valign="top" align="left">14 (27.4)</td></tr><tr><td valign="top" align="left" scope="row"> Gastrointestinal disorders</td><td valign="top" align="left">10 (19.6)</td><td valign="top" align="left">15 (29.4)</td></tr><tr><td valign="top" align="left" scope="row"> Nervous system disorders</td><td valign="top" align="left">12 (23.5)</td><td valign="top" align="left">13 (25.4)</td></tr><tr><td valign="top" align="left" scope="row"> Respiratory, thoracic, and mediastinal disorders</td><td valign="top" align="left">11 (21.5)</td><td valign="top" align="left">10 (19.6)</td></tr><tr><td valign="top" align="left" scope="row"> Psychiatric disorders</td><td valign="top" align="left">9 (17.6)</td><td valign="top" align="left">8 (15.6)</td></tr><tr><td valign="top" align="left" scope="row"> Vascular disorders, hematological</td><td valign="top" align="left">9 (17.6)</td><td valign="top" align="left">4 (7.8)</td></tr><tr><td valign="top" align="left" scope="row"> Neoplasms benign, malignant, and unspecified</td><td valign="top" align="left">5 (9.8)</td><td valign="top" align="left">8 (15.6)</td></tr><tr><td valign="top" align="left" scope="row"> General disorders and administration site conditions</td><td valign="top" align="left">6 (11.7)</td><td valign="top" align="left">4 (7.8)</td></tr><tr><td valign="top" align="left" scope="row"> Cardiac disorders</td><td valign="top" align="left">3 (5.8)</td><td valign="top" align="left">5 (9.8)</td></tr><tr><td valign="top" align="left" scope="row"> Renal and urinary disorders</td><td valign="top" align="left">4 (7.8)</td><td valign="top" align="left">4 (7.8)</td></tr><tr><td valign="top" align="left" scope="row"> Infections and infestations</td><td valign="top" align="left">5 (9.8)</td><td valign="top" align="left">2 (3.9)</td></tr><tr><td valign="top" align="left" scope="row"> Surgical and medical procedures</td><td valign="top" align="left">3 (5.8)</td><td valign="top" align="left">4 (7.8)</td></tr><tr><td valign="top" align="left" scope="row"> Vascular disorders nonhematological</td><td valign="top" align="left">1 (1.9)</td><td valign="top" align="left">5 (9.8)</td></tr></tbody></table></div>aAdverse events are defined according to the Medical Dictionary for Regulatory Activities terminology. Rates between groups across categories were similar (Fisher exact test, P = .60).bFisher exact test, P = .82.cFisher exact test, P = .36.</transformed-table></extracted-table></extracted-tables-set>